Effectiveness of nirsevimab introduction against respiratory syncytial virus in the Valencian Community: A preliminary assessment.

Autor: Estrella-Porter P; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain; Preventive Medicine, Hospital Clínico Universitario de Valencia, Av. de Blasco Ibáñez 17, 46010 Valencia, Spain. Electronic address: estrella_pab@gva.es., Blanco-Calvo C; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain; Preventive Medicine, Hospital Universitario Doctor Peset, Av. de Gaspar Aguilar 90, 46017 Valencia, Spain., Lameiras-Azevedo AS; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain., Juaneda J; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain; Preventive Medicine, Hospital Universitario y Politécnico La Fe, Av. de Fernando Abril Martorell 106, 46026 Valencia, Spain., Fernández-Martínez S; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain., Gómez-Pajares F; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain., Tempelsman R; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain; Preventive Medicine, Hospital Universitario Doctor Peset, Av. de Gaspar Aguilar 90, 46017 Valencia, Spain., Roig-Sena FJ; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain., Pérez-Panades J; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain., Botella-Rocamora P; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain., Lluch-Rodrigo JA; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain., Pastor-Villalba E; Directorate-General of Public Health, Av. de Catalunya 21, 46021 Valencia, Spain.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Sep 17; Vol. 42 (22), pp. 126030. Date of Electronic Publication: 2024 Jun 03.
DOI: 10.1016/j.vaccine.2024.05.078
Abstrakt: Respiratory syncytial virus (RSV) represents a high burden of disease in children and the primary cause of hospitalization, especially in children under 1 year old. In the Valencian Community (Spain), nirsevimab, a long-acting monoclonal antibody, was introduced for the RSV 2023-2024 season as a universal pre-exposure prophylaxis for high-risk children and those under 6 months old. This study examines its impact, coverage, and effectiveness. The campaign achieved 88.5 % coverage and 73.7 % of effectiveness. Analysis of over 27,000 susceptible children (over 24,000 immunized), showed that those immunized exhibited a threefold reduction in RSV incidence compared to non-immunized ones. To prevent one case, the number needed to immunize (NNI) was 63. Hospitalizations due to acute respiratory infections were almost two times lower in immunized children compared to non-immunized ones (0.9 % vs 1.6 %, respectively). These first results showcase the preliminary positive impact of this public health intervention.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: